Molecular target   Clinical Trial identifier   Agents   Phase   Design overview*   Solid tumor indications   Sponsor   Launched on
CD73  NCT02503774  Oleclumab  I  ➣ Single agent  Advanced solid malignancies  MedImmune  2015
➣ In combination with durvalumab (anti-PD-L1)
NCT03736473  Oleclumab  I  ➣ Single agent  Advanced solid malignancies  AstraZeneca  2018
NCT03773666  Oleclumab  I  ➣ In combination with durvalumab (anti-PD-L1)  Muscle-invasive Bladder Cancer  Dana-Farber Cancer Institute  2018
NCT03267589  Oleclumab  II  ➣ In combination with durvalumab (anti-PD-L1)  Relapsed ovarian cancer  Nordic Society for Gynecologic Oncology  2018
NCT03334617  Oleclumab  II  ➣ In combination with durvalumab (anti-PD-L1)  PD-1/PD-L1 inhibition-resistant NSCLC  AstraZeneca  2018
NCT03742102  Oleclumab  Ib/II  ➣ In combination with durvalumab (anti-PD-L1) and paclitaxel (chemotherapy)  Metastatic Triple Negative Breast Cancer  AstraZeneca  2018
NCT03611556  Oleclumab  Ib/II  ➣ In combination with gemcitabine (chemotherapy) and nab-paclitaxel (chemotherapy)  Metastatic pancreatic cancer  MedImmune  2018
➣ In combination with gemcitabine and nab-paclitaxel and durvalumab (anti-PD-L1)
➣ In combination with mFOLFOX (chemotherapy regimen comprising oxaliplatin, leucovorin, 5-FU)
NCT03381274  Oleclumab  Ib/II  ➣ In combination with osimertinib (EGFRT790Minhibitor)  Advanced NSCLC  MedImmune  2018
➣ In combination with AZD4635 (A2Aantagonist)
NCT02754141  BMS-986179  I/IIa  ➣ Single agent  Advanced solid malignancies  Bristol-Myers Squibb  2016
➣ In combination with nivolumab (anti-PD-1)
➣ In combination with rHuPH20 (drug deliveryenzyme)
NCT03454451  CPI-006  I/Ib  ➣ Single agent  Advanced solid malignancies  Corvus Pharmaceuticals  2018
➣ In combination with CPI-444 (A2Aantagonist)
➣ In combination with pembrolizumab (anti-PD-1)
NCT03549000  NZV930  I/Ib  ➣ Single agent  Advanced solid malignancies  Novartis  2018
➣ In combination with spartalizumab (anti-PD-1)
➣ In combination with NIR178 (A2Aantagonist)
➣ In combination with NIR178 andspartalizumab
CD38  NCT03473730  Daratumumab  I  ➣ Single agent  Metastatic Renal Cell Carcinoma or Muscle Invasive Bladder Cancer  M.D. Anderson Cancer Center  2017
A2A  NCT02403193  NIR178  I/Ib  ➣ Single agent  Advanced NSCLC  Palobiofarma  2015
➣ In combination with spartalizumab (anti-PD-1)
NCT03207867  NIR178  II  ➣ Single agent  Advanced solid malignancies  Novartis  2017
➣ In combination with spartalizumab (anti-PD-1)
NCT03742349  NIR178  Ib  ➣ In combination with spartalizumab (anti-PD-1) and LAG525(anti-LAG3)  Triple-negative Breast Cancer  Novartis  2018
NCT02655822  CPI-444  I/Ib  ➣ Single agent  Advanced solid malignancies  Corvus Pharmaceuticals  2016
➣ In combination with atezolizumab (anti-PD-L1)
NCT03337698  CPI-444  Ib/II  ➣ Single agent  Metastatic NSCLC  Hoffmann-La Roche  2017
➣ In combination with atezolizumab (anti-PD-L1)
NCT02740985  AZD4635  I  ➣ Single agent  Advanced solid malignancies  AstraZeneca  2016
➣ In combination with durvalumab (anti-PD-L1)
A2B  NCT03274479  PBF-1129  I  ➣ Single agent  Advanced NSCLC  Palobiofarma  2018